Endonovo Expands SofPulse Commercialization
LOS ANGELES, CA, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced the commercialization and further advancement of its proprietary product – SofPulse®.
Alan Collier, CEO of Endonovo Therapeutics, stated, “We are pleased to announce the positive performance of our SofPulse® units which have been delivered and utilized to date. The Company has received numerous calls and emails from medical professionals and patients alike, detailing the beneficial results stemming from the use of SofPulse®. We believe this performance further reinforces and validates the commercial maturity of SofPulse® while demonstrating the capacity to address medical issues without patients being prescribed and dependent on opioids.”
The company his initiated additional sales and marketing strategies to ensure future growth:
- The company is in the process of hiring an independent sales force; and
- Management is pleased with the ongoing efforts as related to an agreement recently announced with US Authentic Trading Company to handle distribution throughout hospitals in China. We anticipate definitive agreements to be executed in the first quarter of 2019.
“As we conclude 2018, we primarily needed to focus on retaining ownership of SofPulse®. We are pleased to announce we successfully paid the balance of the purchase price of the SofPulse® technology due to the former owners. Additionally, we have successfully established significant sales and distribution agreements and partnerships, where we are now well poised to focus and execute on our new sales initiatives entering 2019,” commented Mr. Collier. “Our sales and marketing strategies are now being implemented globally as we enter a significantly broader commercialization of SofPulse®.”
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki